NCT04560452Completed
Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients
A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Olaparib in Clinical Practice Among Chinese Patients.
Source: ClinicalTrials.gov · Last updated 8 Jul 2026
Brief summary (registry, in English)
This is a multi-centre, prospective, non-interventional study. The study will enrol about 860 Chinese cancer patients from around 56 sites. For OC cohort, the subjects who had received olaparib for at least one dose before study enrolment in real world practices will be enrolled ( n=800) . For PC cohort, according to the doctor's decision, patients who have prescribed and agreed to start taking at least one dose of Olaparib will be enrolled ( n=60). Patient's treating physician is in charge of prescribing (including dose-adjusting or interruption) or discontinuation of olaparib.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1018 (actual)
- First submitted
- 7 Sept 2020
- Start date
- 15 Mar 2021
- Primary completion date
- 5 Sept 2025
- Lead sponsor
- AstraZeneca
- Diseases
- Prostate cancer, Ovarian cancer, Childhood cancers
- NCT number
- NCT04560452
What you commit to
- Study type: Observational
- Participants enrolled: 1018
- From 15 Mar 2021 to the primary completion date, 5 Sept 2025
- 37 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- In other ongoing studies, which prohibit any participation in this non-interventional study judged by investigator.
Who the study is looking for
- Provision of signed and dated written informed consent by the patient or legally acceptable representative prior to any study-specific procedures
- Patients diagnosed as olaparib approved tumor types in China
- Eligible for olaparib treatment per the judgement of the treating physician in clinical practice
- For OC cohort: at least take one tablet of olaparib before enrolment
- For PC cohort: according to the doctor's decision, have prescribed and agreed to start taking at least one dose of Olaparib
Sex: All · Does not accept healthy volunteers
Sites (37)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.